Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Pulse Biosciences ( (PLSE) ) has provided an update.
On January 8, 2026, Pulse Biosciences elected veteran healthtech executive Maria Sainz to its board of directors and appointed her to the audit committee, with the addition formally announced in a January 9, 2026 press release. Sainz, currently president and CEO of portable MRI maker Hyperfine, brings more than three decades of experience leading public and venture-backed medical device companies through clinical, regulatory, financing and M&A milestones, and will receive standard non-employee director cash retainers, the option to convert retainers into equity, reimbursement of board-related expenses, and time-vested stock option grants that further align her incentives with shareholders. The appointment adds deep commercialization and strategic expertise as Pulse advances its first three nsPFA-based programs through key clinical, regulatory and commercial milestones, underscoring the company’s intention to strengthen governance and bolster its ability to compete and scale in interventional and surgical device markets.
The most recent analyst rating on (PLSE) stock is a Hold with a $14.00 price target. To see the full list of analyst forecasts on Pulse Biosciences stock, see the PLSE Stock Forecast page.
Spark’s Take on PLSE Stock
According to Spark, TipRanks’ AI Analyst, PLSE is a Neutral.
Overall score is held back mainly by very weak financial performance (minimal revenue, negative gross profit, and significant cash burn). Offsetting factors include a relatively solid balance sheet and constructive clinical/regulatory progress highlighted on the earnings call, while technicals and valuation remain neutral-to-unfavorable due to a longer-term downtrend and loss-making status.
To see Spark’s full report on PLSE stock, click here.
More about Pulse Biosciences
Pulse Biosciences, Inc. (Nasdaq: PLSE) is a bioelectric medicine company developing its proprietary nPulse technology, which delivers nanosecond pulsed field ablation (nsPFA) energy to non-thermally clear cells while sparing adjacent noncellular tissue. The company is focused on applying this platform to treat atrial fibrillation and a small number of other large clinical markets, including surgical soft tissue ablation, with the aim of improving outcomes for patients and healthcare providers.
Average Trading Volume: 170,640
Technical Sentiment Signal: Hold
Current Market Cap: $1.03B
Learn more about PLSE stock on TipRanks’ Stock Analysis page.